279 related articles for article (PubMed ID: 27186620)
1. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
[TBL] [Abstract][Full Text] [Related]
2. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
[No Abstract] [Full Text] [Related]
3. ▼Relvar Ellipta for COPD.
Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
[TBL] [Abstract][Full Text] [Related]
4. Relvar Ellipta for asthma.
Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
[TBL] [Abstract][Full Text] [Related]
5. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
Wolthers OD
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
[TBL] [Abstract][Full Text] [Related]
7. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
McKeage K
Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
[TBL] [Abstract][Full Text] [Related]
8. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
Kempsford R; Norris V; Siederer S
Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
[TBL] [Abstract][Full Text] [Related]
9. Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).
Lal C; Strange C
Expert Opin Pharmacother; 2019 Jun; 20(9):1075-1085. PubMed ID: 30983423
[TBL] [Abstract][Full Text] [Related]
10. Vilanterol fluticasone and mortality in comorbid COPD GOLD B.
Brusselle G
Lancet; 2016 Apr; 387(10030):1791-2. PubMed ID: 27203487
[No Abstract] [Full Text] [Related]
11. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
[TBL] [Abstract][Full Text] [Related]
12. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
13. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
[TBL] [Abstract][Full Text] [Related]
14. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
15. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
Antohe I; Antoniu SA; Gavrilovici C
Expert Opin Pharmacother; 2018 Feb; 19(3):287-289. PubMed ID: 29271268
[TBL] [Abstract][Full Text] [Related]
16. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Caramori G; Ruggeri P; Casolari P; Chung KF; Girbino G; Adcock IM
Expert Rev Respir Med; 2017 Dec; 11(12):955-967. PubMed ID: 28956463
[TBL] [Abstract][Full Text] [Related]
18. Fluticasone-vilanterol combination approved for COPD.
Traynor K
Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869
[No Abstract] [Full Text] [Related]
19. The lung study promising a breath of fresh air in research world.
Limb M
BMJ; 2015 Nov; 351():h6343. PubMed ID: 26613902
[No Abstract] [Full Text] [Related]
20. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Matera MG; Capuano A; Cazzola M
Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
